Reckitt Sees End Of Mucinex Exclusivity Despite Delay Attempts
This article was originally published in The Tan Sheet
Executive Summary
Reckitt Benckiser expects to lose OTC exclusivity for its Mucinex cough cold line as early as 2011 even as it attempts to delay private label competition
You may also be interested in...
Mucinex Patent Ruling Breathes Life Into Watson And Perrigo ANDAs
Watson Pharmaceuticals' success against Reckitt Benckiser's Mucinex patent infringement suit could clear a path for Mucinex equivalents to launch in the first half of 2011.
Mucinex Patent Ruling Breathes Life Into Watson And Perrigo ANDAs
Watson Pharmaceuticals' success against Reckitt Benckiser's Mucinex patent infringement suit could clear a path for Mucinex equivalents to launch in the first half of 2011.
Mucinex Patent Ruling Breathes Life Into Watson And Perrigo ANDAs
Watson Pharmaceuticals' success against Reckitt Benckiser's Mucinex patent infringement suit could clear a path for Mucinex equivalents to launch in the first half of 2011.